Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

about

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

Item

http://www.wikidata.org/entity/Q28073320

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

@ast

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

@en

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

@nl

type

Item

label

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

@ast

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

@en

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

@nl

prefLabel

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

@ast

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

@en

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

@nl

P1476

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer

@en

P2093

Benrashid M

http://www.w3.org/2001/XMLSchema#string

Cox H

http://www.w3.org/2001/XMLSchema#string

Hames M

http://www.w3.org/2001/XMLSchema#string

P2860

Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

Alpha emitter radium-223 and survival in metastatic prostate cancer

Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone.

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.

Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases.

Radiation-based approaches for therapy and palliation of advanced prostate cancer.

Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.

Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.

Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.

P304

565-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6004/JADPRO.2015.6.6.5

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27648346

http://www.w3.org/2001/XMLSchema#string

P932

5017547

http://www.w3.org/2001/XMLSchema#string